Showing 881-890 of 1110 results for "".
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel
- Allegro Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEOhttps://modernod.com/news/allegro-prepares-to-take-lead-compound-risuteganib-to-phase-3-appoints-new-ceo/2479926/Allegro Ophthalmics announced that its board of directors has named Hampar Karageozian to the position of Executive Chairman and has appointed Vicken Karageozian, MD, to the position of President and Chief Executive O
- Vance Thompson Vision Announces New Clinic and LASIK and Cataract Center in Omahahttps://modernod.com/news/vance-thompson-vision-announces-new-clinic-and-lasik-and-cataract-center-in-omaha/2480189/Vance Thompson Vision is scheduled to open a new clinic in Omeha, Nebraska, in August and will include a focus on cataract surgery, minimally invasive glaucoma surgery, LASIK, and corneal surgery. Brandon Baartman, MD, is an accomplished refractive, cataract,
- Monica Jong, PhD, Appointed Global Professional Education Lead, Myopia at Johnson & Johnson Visionhttps://modernod.com/news/monica-jong-phd-appointed-global-professional-education-lead-myopia-at-johnson-johnson-vision/2480309/Monica Jong, PhD, co-founder of the
- Johnson & Johnson Vision Receives FDA Clearance for Catalys cOS 6.0 Software for Astigmatism Managementhttps://modernod.com/news/johnson-johnson-vision-recevies-fda-clearance-for-catalys-cos-6-0-software-for-astigmatism-management/2477915/The FDA has granted 510(k) clearance for new software for the Catalys Precision Laser System that aims to simplify astigmatism management workflow and increase operational efficiency. The Catalys cOS 6.0 software with advanced astigmatism management is a collaboration with Cassini Technolog
- Johnson & Johnson Vision Ceases Customer-Facing Operations for Sightbox Online Contact Lens Subscription Servicehttps://modernod.com/news/johnson-johnson-vision-ceases-customer-facing-operations-for-sightbox-online-contact-lens-subscription-service/2477054/
- Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunthttps://modernod.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.
- Navigate Patient Solutions Adds Ophthalmology Leaders to its Medical Advisory Boardhttps://modernod.com/news/navigate-patient-solutions-adds-ophthalmology-leaders-to-its-medical-advisory-board/2482835/Navigate Patient Solutions announced the addition of Vance Thompson, MD; David Cox, and Matthew P. Jensen to its Medical Advisory Board. Navigate is developing a patient engagement solution for ophthalmology. The startup partners with ophthal
- CIRM Awards $4.7 Million for Vision Loss Gene Therapyhttps://modernod.com/news/cirm-awards-47-million-for-vision-loss-gene-therapy/2482827/The California Institute for Regenerative Medicine (CIRM) awarded $4.7 million to Blue Gen Therapeutics Foundation (Principal Investigator Aaron Nagiel, MD, PhD) to fund preclinical research that aims to develop a gene therapy for the rare disease blue cone monochromacy (BCM). <
- Perfuse Therapeutics Announces Positive Results from Phase 1/2a Trial of PER-001 Intravitreal Implant in Patients with Glaucomahttps://modernod.com/news/perfuse-therapeutics-announces-positive-results-from-phase-12a-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma/2482794/Perfuse Therapeutics announced positive 24-week results from its completed phase 1/2a trial of PER-001, a first in class endothelin antagonist intravitreal implant for glaucoma. Steven Mansberger, MD, MPH, Chief of Ophthalmology and Director of Gl